Edition:
United Kingdom

aTyr Pharma Inc (LIFE.O)

LIFE.O on Nasdaq

4.05USD
22 Sep 2017
Change (% chg)

-- (--)
Prev Close
$4.05
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
45,206
52-wk High
$4.45
52-wk Low
$2.10

Chart for

About

aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based... (more)

Overall

Beta: --
Market Cap(Mil.): $120.33
Shares Outstanding(Mil.): 29.71
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 60.89 15.95
EPS (TTM): -- -- --
ROI: -- 0.19 15.19
ROE: -- 2.32 13.87

BRIEF-Atyr Pharma files for resale of up to 23.6 mln shares of common stock by selling stockholders - SEC Filing‍​

* Atyr Pharma Inc files for resale of up to 23.6 million shares of common stock by selling stockholders - SEC Filing‍​ Source text: [http://bit.ly/2h4V7rA] Further company coverage:

14 Sep 2017

BRIEF-‍Viking Global Investors reports 9.5 pct passive stake in aTyr Pharma​

* ‍Viking Global Investors Lp reports 9.5 percent passive stake in aTyr Pharma Inc as on August 31, 2017 - SEC filing​ Source text : (http://bit.ly/2vP2d66) Further company coverage:

11 Sep 2017

BRIEF-Atyr Pharma qtrly ‍net loss per share $0.51​

* Atyr Pharma announces second quarter 2017 operating results and provides an update on innovative immunology pipeline

14 Aug 2017

BRIEF-ATyr pharma enters into first amendment to loan and security agreement

* ATyr Pharma says on june 30, entered into first amendment to loan and security agreement with silicon valley bank and solar capital ltd - SEC filing

05 Jul 2017

BRIEF-aTyr Pharma announces qtrly net loss per share, basic and diluted $0.56

* aTyr Pharma Inc - Qtrly net loss per share, basic and diluted $0.56

11 May 2017

BRIEF-Atyr Pharma announces promising top-line results from Resolaris

* Atyr Pharma announces promising top-line results from Resolaris phase 1B/2 clinical trial in patients with early onset facioscapulohumeral muscular dystrophy

24 Apr 2017

BRIEF-aTyr Pharma appoints of Timothy P. Coughlin to its board

* aTyr Pharma announces appointment of TIMOTHY P. COUGHLIN to its board of directors Source text for Eikon: Further company coverage:

10 Apr 2017

Earnings vs. Estimates